Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Natera Inc - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
NTRA
Nasdaq
2835
https://www.natera.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Natera Inc
11 Best Healthcare ETFs To Buy Now
- Mar 21st, 2024 2:25 pm
Will Natera (NTRA) Continue to Deliver Solid Topline Growth?
- Mar 20th, 2024 9:46 am
Genetic Testing Stock Nears Buy Point After Earnings Gap-Up And 45% Gain
- Mar 18th, 2024 7:39 pm
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
- Mar 18th, 2024 11:00 am
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
- Mar 14th, 2024 12:00 pm
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
- Mar 12th, 2024 12:00 pm
SEC and Chief Legal Officer Daniel Rabinowitz Sells Shares of Natera Inc (NTRA)
- Mar 8th, 2024 6:31 am
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
- Mar 7th, 2024 1:00 pm
What Makes Natera (NTRA) a Strong Momentum Stock: Buy Now?
- Mar 4th, 2024 5:00 pm
Natera Full Year 2023 Earnings: Beats Expectations
- Mar 2nd, 2024 12:38 pm
Decoding Natera Inc (NTRA): A Strategic SWOT Insight
- Mar 1st, 2024 5:09 am
Q4 2023 Natera Inc Earnings Call
- Feb 29th, 2024 4:06 pm
Natera, Inc. (NASDAQ:NTRA) Q4 2023 Earnings Call Transcript
- Feb 29th, 2024 1:12 pm
Natera to Participate in March Investor Conferences
- Feb 29th, 2024 1:00 pm
Compared to Estimates, Natera (NTRA) Q4 Earnings: A Look at Key Metrics
- Feb 28th, 2024 11:30 pm
Natera Inc (NTRA) Reports Significant Revenue Growth and Improved Gross Margins in Full Year 2023
- Feb 28th, 2024 9:32 pm
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
- Feb 28th, 2024 9:05 pm
Natera (NTRA) Management Increased Full Year Guidance
- Feb 27th, 2024 1:12 pm
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
- Feb 27th, 2024 1:00 pm
Natera secures Medicare coverage for cancer test in 2 new indications
- Feb 27th, 2024 6:07 am
Scroll